Premier Alternatives

TRexBio

South San Francisco, CA · Founded 2018 · Privately Held (backing)

Developer of immunoregulatory medicines designed to restore immune balance in inflammatory diseases through tissue regulatory T cell biology. TRexBio is based in South San Francisco, CA and was founded in 2018. It is valued at about $274 million as of Oct 2026, set by institutional fund marks. It has raised $222 million.

PMV mark · valuation
$274.0M
Oct 2026
Priced at
—
Total raised
$222.1M
Last round
—

TRexBio key facts

as of Oct 2026
  • Developer of immunoregulatory medicines designed to restore immune balance in inflammatory diseases through tissue regulatory T cell biology.
  • TRexBio is valued at approximately $274.0M as of Oct 2026, per PrivateMarketView’s mark.
  • It has raised $222.1M; the latest was Later Stage VC ($50.0M) in Jan 2026.
  • Notable investors include Alexandria Venture Investments, Johnson & Johnson JJDC, Polaris Partners, SV Health Investors, Pfizer Ventures — 14 tracked in total.
  • 4 institutional filers report fund marks on TRexBio across 13 filings.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$274.0M

Reported valuation; nothing comparable since.

set by institutional fund marksas of Oct 2026question about this number?
Free account
More of TRexBio with a free account
  • ·The complete investor list: 14 names
  • ·Watch TRexBio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Institutional fund marks on TRexBio

4 filers · latest Oct 2025

4 SEC-registered funds reported 13 fair-value marks on TRexBio between Apr 2025 and Oct 2025. Filer-level marks and implied $/share are available to Pro members.

Unlock 13 fund marks

Membership and data by Private Market View

Every name the funds mark, next to where it trades →

TRexBio funding rounds

No rounds on record

No funding rounds for TRexBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

TRexBio valuation

TRexBio is valued at approximately $274 million as of Oct 2026. The figure is set by institutional fund marks.

Institutional holders and vehicles

4 SEC-registered funds reported 13 fair-value marks on TRexBio between Apr 2025 and Oct 2025, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

TRexBio investors

14 investors are on record for TRexBio, including Alexandria Venture Investments, Johnson & Johnson JJDC, Polaris Partners and SV Health Investors. By type, the record holds 3 venture capital firms and 3 hedge funds.

About TRexBio

Developer of immunoregulatory medicines designed to restore immune balance in inflammatory diseases through tissue regulatory T cell biology. The company offers a Deep Biology platform leveraging computational biology tools, human tissue analysis, and deep immunobiology expertise, enabling patients with inflammatory and autoimmune conditions to benefit from therapies that activate and expand tissue regulatory T cells for improved disease control.

Sector
Healthcare
HQ
South San Francisco, CA, United States
Founded
2018
Employees
57
Website
trex.bio/
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.